Zimmer Biomet (ZBH) Expected to Announce Earnings on Tuesday

Zimmer Biomet (NYSE:ZBH) is expected to release its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect Zimmer Biomet to post earnings of $1.86 per share and revenue of $2.0555 billion for the quarter. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:30 AM ET.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same period in the prior year, the company posted $2.31 EPS. The company’s revenue was up 10.9% compared to the same quarter last year. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $95.46 on Tuesday. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. Zimmer Biomet has a 1 year low of $84.59 and a 1 year high of $108.29. The company has a market cap of $18.48 billion, a PE ratio of 26.97, a PEG ratio of 1.94 and a beta of 0.61. The company’s 50-day moving average is $93.77 and its two-hundred day moving average is $93.21.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is presently 27.12%.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. This represents a 20.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.28% of the stock is currently owned by company insiders.

Institutional Trading of Zimmer Biomet

Institutional investors and hedge funds have recently modified their holdings of the stock. DV Equities LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $25,000. Gen Wealth Partners Inc bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $31,000. Headlands Technologies LLC bought a new stake in shares of Zimmer Biomet in the 2nd quarter valued at about $37,000. EFG International AG bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $55,000. Finally, Mpwm Advisory Solutions LLC bought a new stake in shares of Zimmer Biomet in the 3rd quarter valued at about $65,000. 88.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ZBH. TD Cowen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. William Blair began coverage on shares of Zimmer Biomet in a research report on Friday, February 20th. They set a “market perform” rating on the stock. Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and upped their target price for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Barclays cut their target price on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a research report on Thursday, February 12th. Finally, UBS Group restated a “sell” rating and set a $89.00 target price on shares of Zimmer Biomet in a research report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $105.95.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.